Baseline TNF-α in relation to inflammatory burden, infliximab pharmacokinetics, and dose intensification in pediatric Crohn's disease.
Kwon Yiyoung Y, Kim Eun Sil ES, Kim Yoon Zi YZ, Jeong Tae Jong TJ et al.
Crohn's disease (CD) is a systemic disorder in which conventional luminal endoscopic assessments may incompletely reflect overall inflammatory burden. We aimed to evaluate the associations between baseline inflammatory cytokines, disease phenotype, infliximab (IFX) pharmacokinetics, and the need for dose intensification (DI) in pediatric CD. This prospective study included pediatric patients with moderate-to-severe CD treated with IFX. Tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) levels were measured at diagnosis. Baseline imbalances were adjusted using propensity score matching and inverse probability of treatment weighting analyses. Of the 160 enrolled patients, 15 (9.4%) were not included in the 1-year analysis, and 145 (90.6%) completed the 1-year follow-up. Body mass index (BMI)-adjusted TNF-α levels correlated with erythrocyte sedimentation rate (R = 0.22, p = 0.008) and fecal calprotectin (R = 0.34, p < 0.001), but not with simple endoscopic score for CD. In contrast, IL-6 levels were not significantly associated with inflammatory biomarkers. Cytokine profiles and IFX trough levels were not associated with perianal disease status or disease location. DI was required in 94 of 145 patients (64.8%), and patients requiring DI demonstrated higher baseline TNF-α levels than those without DI (49.63 ± 29.09 vs. 40.14 ± 16.59 pg/mL, p = 0.046). Higher baseline TNF-α levels were associated with subsequent IFX DI, while also correlating with conventional inflammatory biomarkers but not with SES-CD or anatomical disease phenotype. These findings suggest that baseline TNF-α may reflect an aspect of inflammatory burden relevant to subsequent treatment requirements that is not captured by luminal endoscopic severity or anatomical disease classification alone.